 |
BioWorld-International-2010-01-13
Galapagos Scores Biggest Deal Yet: 400M Pact with Roche
Adocia Raises €14M to Boost Protein Chaperone Technology
No Abstract
BioWorld International Correspondent
Adocia SA raised €14 million (US$20.3 million) in a second funding round to continue development of its BioChaperone protein delivery technology, which is designed to prolong the localized activity of growth factors and other protein-based drugs at their sites of action. The company, based in Lyon, France, has filed investigational new drug applications on its first two development programs, and clinical trials are due to begin shortly.
Galapagos Scores Biggest Deal Yet: €400M Pact with Roche
LONDON - Galapagos NV cemented its reputation as a drug discovery partner of choice for big pharma, signing a potential €400 million (US$579.6 million) deal with F. Hoffmann-La Roche Ltd. in both small-molecule and antibody treatments for chronic obstructive pulmonary disease (COPD). (BioWorld International)
BioWorld International Correspondent